BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. Read more about BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic. Read more about Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic.
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Read more about Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women. Read more about Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.
Response to Pisano, Gastonis, Sparano, et al. Read more about Response to Pisano, Gastonis, Sparano, et al.
Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Read more about Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children.
Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. Read more about Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. Read more about Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research.
Common Susceptibility Loci for Male Breast Cancer. Read more about Common Susceptibility Loci for Male Breast Cancer.
Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Read more about Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
